Advantages of low dose steroid from the day after renal transplantation

M G McGeownC M Hill


We have used a low dose of steroid (20 mg of prednisolone), commencing the day after transplantation, for 151 consecutive renal transplants in 141 patients. Five patients received grafts from living related donors, 146 received cadaver grafts. All patients received azathioprine for routine immunosuppression and the first 47 received a single dose of actinomycin C i.v. for treatment of rejection. No other immunosuppressive drugs were used. This treatment provided satisfactory immunosuppression as 109 of 151 grafts continue to function for periods of 3 months to 10 years and, of 42 grafts lost, only 17 failed from rejection. The cumulative survival of first cadaver grafts at 1 and 2 years in recipients of all ages (7 to 55 years) was 77.9 and 76.0%, respectively; in recipients 15 to 34 years old, 90.9 and 86.1%, respectively. Twenty-three patients died, no patient died from infection during the admission for transplantation, and infection played a part in the deaths of only four patients. The incidence of other complications was low; seven patients developed gastrointestinal complications, one died, four patients developed diabetes, all survived; only one patient developed avascular necrosis of bone.


May 1, 1990·Transplant International : Official Journal of the European Society for Organ Transplantation·W RiegelW H Hörl
Jan 1, 1997·Archives of Orthopaedic and Trauma Surgery·B FinkW Rüther
Feb 1, 1993·Digestive Diseases and Sciences·J Y Kang
Sep 1, 1989·Klinische Wochenschrift·W H HörlH Wilms
Apr 1, 1995·Irish Journal of Medical Science·P J ConlonJ J Walshe
Dec 7, 2000·Diabetes Research and Clinical Practice·J H NamK B Huh
May 8, 1986·The New England Journal of Medicine·Canadian Multicentre Transplant Study Group
Aug 21, 2004·Annals of Surgery·Arthur J MatasDavid E R Sutherland
Jul 1, 1990·Transplant International : Official Journal of the European Society for Organ Transplantation·H IsoniemiP Häyry
Sep 29, 2004·Paediatric Drugs·Jayakumar R Vidhun, Minnie M Sarwal
Apr 1, 1987·Scandinavian Journal of Gastroenterology·K Ala-Kaila
Nov 30, 2006·Diabetes & Metabolism·A Penfornis, S Kury-Paulin
Mar 5, 2002·Diabetes Care·Victor M MontoriYogish C Kudva
Nov 27, 2009·Journal of Neuroimmunology·Alessandra AldinucciClara Ballerini
Dec 1, 1989·Transplant International : Official Journal of the European Society for Organ Transplantation·M J DennisR W Blamey
Feb 20, 2003·International Journal of Immunopathology and Pharmacology·H. Sakamoto, M. Kurabayashi
Jul 23, 1983·The Medical Journal of Australia·T H Mathew
Oct 30, 1982·The Medical Journal of Australia·J F MahonyJ H Stewart
Apr 19, 2002·Journal of the American Society of Nephrology : JASN·Roy D BloomKevin C Mange

Related Concepts

Azathioprine sodium
Diabetes Mellitus
Cholera Infantum
Graft Survival
Hydrocortisone, (9 beta,10 alpha,11 alpha)-Isomer
Avascular Necrosis of Bone
Transplantation, Homologous

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.